ONWARD Medical Celebrates Transformative Year in 2024
ONWARD Medical N.V. (Euronext: ONWD), a pioneering medical technology company, experienced significant advancements in 2024, culminating in critical milestones aimed at enhancing the quality of life for individuals with spinal cord injuries (SCI) and other movement disabilities.
CEO Dave Marver proudly stated, "The year 2024 marked a transformative period for ONWARD, characterized by our FDA De Novo authorization and the successful commercial rollout of the ARC-EX System. With the backing of strategic partners like Ottobock, we have not only strengthened our financial position but have also expanded our innovative technology portfolio. The journey of the ARC-EX System into the market represents our commitment to delivering life-changing therapies to patients in need."
Highlights from 2024 and Early 2025
Clinical and Developmental Achievements
Throughout 2024, ONWARD made significant strides in its clinical and development initiatives, with several notable achievements:
- The expansion of the HemON clinical feasibility study included Sint Maartenskliniek, setting the stage for a global pivotal trial called Empower BP, aimed at assessing the efficacy of ARC-IM Therapy in improving blood pressure stability.
- In a remarkable move, the company received Breakthrough Device Designation (BDD) from the FDA for the ARC-BCI System, integrating advanced brain-computer interface technology to support users in restoring voluntary movement after SCI.
- Acceptance into the FDA's Total Product Lifecycle Advisory Program (TAP) highlighted ONWARD's dedication to innovative healthcare solutions.
Intellectual Property Expansion
In a strategic maneuver, ONWARD expanded its intellectual property portfolio by adding 20 patents in 2024, bringing the total to over 150 patents issued. This growth solidifies ONWARD's position as a leader in spinal cord stimulation therapies.
Commercial Developments: Gaining Traction
Product Launches and Recognition
In 2024, ONWARD established its presence in the market with the release of the ARC-EX System, which received praise and recognition as one of TIME Magazine’s Best Inventions. Following the first commercial sales to prestigious institutions, like UW Medicine and Next Steps Chicago, ONWARD demonstrated a proactive approach in advancing healthcare technology accessibility.
Financial Overview for 2024
Financially, ONWARD reported an operating loss of EUR 34.9M in 2024, slightly improving from EUR 35.5M in 2023. The total revenues increased, driven primarily by a notable rise in grant income from various funding initiatives, which tallied EUR 1.7M compared to EUR 0.5M in the previous year.
Outlook for 2025: Paving the Path Forward
Looking ahead, 2025 holds the promise of significant advancements for ONWARD. The company is set to embark on various engineering, clinical, and regulatory initiatives:
- A robust pipeline of technologies targeting SCI and other movement disorders, including submissions for regulatory applications to expand the ARC-EX System’s reach to home settings.
- Continued investment and research into therapies aimed at restoring bladder function and addressing movement challenges associated with Parkinson's disease.
- A strong commitment to enhancing patient accessibility to its innovative therapies through direct marketing strategies and planned expansion across Europe.
ONWARD's ongoing efforts reflect a steadfast commitment to providing innovative solutions that enhance patient quality of life. As the company continues to pioneer new technologies that connect the mind with movement, its impact on the field of rehabilitation remains profound.
Frequently Asked Questions
1. What is the focus of ONWARD Medical?
ONWARD Medical specializes in developing innovative spinal cord stimulation therapies aimed at restoring movement and independence for individuals with spinal cord injuries.
2. What were the financial results for ONWARD in 2024?
In 2024, ONWARD reported an operating loss of EUR 34.9M, with total revenues increasing to EUR 1.7M, mainly driven by grant income.
3. What significant partnerships did ONWARD establish?
ONWARD secured a strategic investment from Ottobock, enhancing their financial stability and collaborative capabilities.
4. What innovations does ONWARD Medical plan for 2025?
For 2025, ONWARD is focused on expanding its ARC-EX System to home settings, advancing clinical trials for bladder function restoration, and growing its market presence in Europe.
5. How does ONWARD Medical stand in terms of intellectual property?
As of 2024, ONWARD holds over 150 issued patents, positioning itself as a leader in the spinal cord stimulation technology field.
